3.2 C
New York
Wednesday, February 1, 2023

There Is A Quest For Clarity Surrounding Acorda Therapeutics Inc. (NASDAQ: ACOR) Volatility

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Acorda Therapeutics Inc. (ACOR) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.0271, or 3.80%, to $0.74. The Acorda Therapeutics Inc. has recorded 323,936 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $0.71 and fluctuated between $0.8300 as its day high and $0.7011 as its day low. The current market capitalization of Acorda Therapeutics Inc. is $15.06M. A total of 0.55 million shares were traded on the day, compared to an average of 3.83M shares.

Insider trades can also provide insight into a stock’s future direction. During the recent three months, ACOR has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 3 SELLs from insiders. Insiders purchased 0 shares during that period but sold 5,311.

In the most recent transaction, COHEN RON sold 2,289 shares of ACOR for 1.70 per share on Mar 17. After the transaction, the President and CEO now owns 129,601 company shares.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for ACOR in the last 3 months, the mean price target is $10.00 with high estimates of $10.00 and low estimates of $10.00. In terms of 52-week highs and lows, ACOR has a high of $2.51 and a low of $0.26.

As of this writing, ACOR has an earnings estimate of $0 per share for the current quarter. EPS was calculated based on a consensus of 0 estimates, with a high estimate of $0 per share and a lower estimate of $0. The company reported an EPS of -$1.87 in the last quarter, which was 10.50% higher than expectations of -$2.09.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 1 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ACOR is Buy with a score of 0.00. A total of 1 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles